The adrenergic contribution to glucose counterregulation in type I diabetes mellitus. Dependency on A-cell function and mediation through beta2-adrenergic receptors

P. de Feo, G. Bolli, G. Perriello, S. De Cosmo, P. Compagnucci, G. Angeletti, F. Santeusanio, J. E. Gerich, M. Motolese, P. Brunetti

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

In order to assess the adrenergic contribution to hypoglycemic glucose counterregulation in type I diabetes mellitus and to determine whether the adrenergic contribution is mediated through beta1- or beta2-adrenergic receptors, hypoglycemia was induced by an i.v. insulin infusion (30 mU/m2 · min) for 60 min in 11 insulin-dependent diabetic patients (IDDM), 5 with normal plasma glucagon responses and 6 with blunted responses, and also in 7 age-weight-matched nondiabetic subjects. Rates of plasma glucose decrease and postnadir increase, as well as plasma concentrations of free insulin and of counterregulatory hormones, were measured when insulin was infused alone, and when insulin was infused along with propranolol (a beta1- and beta2-adrenergic receptor antagonist) or metoprolol (a selective beta1-antagonist). Postnadir plasma glucose recovery was decreased in IDDM with blunted plasma glucagon responses (21 ± 0.8 μmol · L-1, P <0.001), but was normal in patients with normal plasma glucagon responses (30 ± 0.4 versus 33 ± 0.5 μmol · L-1 · min-1 in nondiabetic subjects, P = NS). Postnadir plasma glucose recovery was not affected by either propranolol or metoprolol in normal subjects and in IDDM with normal glucagon responses. However, in IDDM with blunted plasma glucagon responses, postnadir plasma glucose recovery was further decreased by propranolol (14 ± 0.6 μmol · L-1 · min-1, P <0.01), but was unaffected by metoprolol (22 ± 0.9 μmol · L-1 · min-1, P= NS). These results demonstrate that, as in normal man, adrenergic mechanisms are not essential for normal plasma glucose recovery from hypoglycemia in IDDM with normal plasma glucagon responses. However, in IDDM with blunted plasma glucagon responses, adrenergic mechanisms become important for glucose counterregulation although they do not fully compensate for the blunted plasma glucagon responses. Since propranolol delayed plasma glucose recovery from hypoglycemia in IDDM with blunted glucagon responses but metoprolol had no effect, the adrenergic contribution to glucose counterregulation appears to be mediated through beta2-adrenergic receptors.

Original languageEnglish
Pages (from-to)887-893
Number of pages7
JournalDiabetes
Volume32
Issue number10
Publication statusPublished - 1983

Fingerprint

Type 1 Diabetes Mellitus
Adrenergic Agents
Adrenergic Receptors
Glucagon
Glucose
Metoprolol
Propranolol
Insulin
Hypoglycemia
Adrenergic Antagonists
Hypoglycemic Agents
Hormones

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The adrenergic contribution to glucose counterregulation in type I diabetes mellitus. Dependency on A-cell function and mediation through beta2-adrenergic receptors. / de Feo, P.; Bolli, G.; Perriello, G.; De Cosmo, S.; Compagnucci, P.; Angeletti, G.; Santeusanio, F.; Gerich, J. E.; Motolese, M.; Brunetti, P.

In: Diabetes, Vol. 32, No. 10, 1983, p. 887-893.

Research output: Contribution to journalArticle

de Feo, P, Bolli, G, Perriello, G, De Cosmo, S, Compagnucci, P, Angeletti, G, Santeusanio, F, Gerich, JE, Motolese, M & Brunetti, P 1983, 'The adrenergic contribution to glucose counterregulation in type I diabetes mellitus. Dependency on A-cell function and mediation through beta2-adrenergic receptors', Diabetes, vol. 32, no. 10, pp. 887-893.
de Feo, P. ; Bolli, G. ; Perriello, G. ; De Cosmo, S. ; Compagnucci, P. ; Angeletti, G. ; Santeusanio, F. ; Gerich, J. E. ; Motolese, M. ; Brunetti, P. / The adrenergic contribution to glucose counterregulation in type I diabetes mellitus. Dependency on A-cell function and mediation through beta2-adrenergic receptors. In: Diabetes. 1983 ; Vol. 32, No. 10. pp. 887-893.
@article{2c601672109d4585b6513055e6133909,
title = "The adrenergic contribution to glucose counterregulation in type I diabetes mellitus. Dependency on A-cell function and mediation through beta2-adrenergic receptors",
abstract = "In order to assess the adrenergic contribution to hypoglycemic glucose counterregulation in type I diabetes mellitus and to determine whether the adrenergic contribution is mediated through beta1- or beta2-adrenergic receptors, hypoglycemia was induced by an i.v. insulin infusion (30 mU/m2 · min) for 60 min in 11 insulin-dependent diabetic patients (IDDM), 5 with normal plasma glucagon responses and 6 with blunted responses, and also in 7 age-weight-matched nondiabetic subjects. Rates of plasma glucose decrease and postnadir increase, as well as plasma concentrations of free insulin and of counterregulatory hormones, were measured when insulin was infused alone, and when insulin was infused along with propranolol (a beta1- and beta2-adrenergic receptor antagonist) or metoprolol (a selective beta1-antagonist). Postnadir plasma glucose recovery was decreased in IDDM with blunted plasma glucagon responses (21 ± 0.8 μmol · L-1, P <0.001), but was normal in patients with normal plasma glucagon responses (30 ± 0.4 versus 33 ± 0.5 μmol · L-1 · min-1 in nondiabetic subjects, P = NS). Postnadir plasma glucose recovery was not affected by either propranolol or metoprolol in normal subjects and in IDDM with normal glucagon responses. However, in IDDM with blunted plasma glucagon responses, postnadir plasma glucose recovery was further decreased by propranolol (14 ± 0.6 μmol · L-1 · min-1, P <0.01), but was unaffected by metoprolol (22 ± 0.9 μmol · L-1 · min-1, P= NS). These results demonstrate that, as in normal man, adrenergic mechanisms are not essential for normal plasma glucose recovery from hypoglycemia in IDDM with normal plasma glucagon responses. However, in IDDM with blunted plasma glucagon responses, adrenergic mechanisms become important for glucose counterregulation although they do not fully compensate for the blunted plasma glucagon responses. Since propranolol delayed plasma glucose recovery from hypoglycemia in IDDM with blunted glucagon responses but metoprolol had no effect, the adrenergic contribution to glucose counterregulation appears to be mediated through beta2-adrenergic receptors.",
author = "{de Feo}, P. and G. Bolli and G. Perriello and {De Cosmo}, S. and P. Compagnucci and G. Angeletti and F. Santeusanio and Gerich, {J. E.} and M. Motolese and P. Brunetti",
year = "1983",
language = "English",
volume = "32",
pages = "887--893",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - The adrenergic contribution to glucose counterregulation in type I diabetes mellitus. Dependency on A-cell function and mediation through beta2-adrenergic receptors

AU - de Feo, P.

AU - Bolli, G.

AU - Perriello, G.

AU - De Cosmo, S.

AU - Compagnucci, P.

AU - Angeletti, G.

AU - Santeusanio, F.

AU - Gerich, J. E.

AU - Motolese, M.

AU - Brunetti, P.

PY - 1983

Y1 - 1983

N2 - In order to assess the adrenergic contribution to hypoglycemic glucose counterregulation in type I diabetes mellitus and to determine whether the adrenergic contribution is mediated through beta1- or beta2-adrenergic receptors, hypoglycemia was induced by an i.v. insulin infusion (30 mU/m2 · min) for 60 min in 11 insulin-dependent diabetic patients (IDDM), 5 with normal plasma glucagon responses and 6 with blunted responses, and also in 7 age-weight-matched nondiabetic subjects. Rates of plasma glucose decrease and postnadir increase, as well as plasma concentrations of free insulin and of counterregulatory hormones, were measured when insulin was infused alone, and when insulin was infused along with propranolol (a beta1- and beta2-adrenergic receptor antagonist) or metoprolol (a selective beta1-antagonist). Postnadir plasma glucose recovery was decreased in IDDM with blunted plasma glucagon responses (21 ± 0.8 μmol · L-1, P <0.001), but was normal in patients with normal plasma glucagon responses (30 ± 0.4 versus 33 ± 0.5 μmol · L-1 · min-1 in nondiabetic subjects, P = NS). Postnadir plasma glucose recovery was not affected by either propranolol or metoprolol in normal subjects and in IDDM with normal glucagon responses. However, in IDDM with blunted plasma glucagon responses, postnadir plasma glucose recovery was further decreased by propranolol (14 ± 0.6 μmol · L-1 · min-1, P <0.01), but was unaffected by metoprolol (22 ± 0.9 μmol · L-1 · min-1, P= NS). These results demonstrate that, as in normal man, adrenergic mechanisms are not essential for normal plasma glucose recovery from hypoglycemia in IDDM with normal plasma glucagon responses. However, in IDDM with blunted plasma glucagon responses, adrenergic mechanisms become important for glucose counterregulation although they do not fully compensate for the blunted plasma glucagon responses. Since propranolol delayed plasma glucose recovery from hypoglycemia in IDDM with blunted glucagon responses but metoprolol had no effect, the adrenergic contribution to glucose counterregulation appears to be mediated through beta2-adrenergic receptors.

AB - In order to assess the adrenergic contribution to hypoglycemic glucose counterregulation in type I diabetes mellitus and to determine whether the adrenergic contribution is mediated through beta1- or beta2-adrenergic receptors, hypoglycemia was induced by an i.v. insulin infusion (30 mU/m2 · min) for 60 min in 11 insulin-dependent diabetic patients (IDDM), 5 with normal plasma glucagon responses and 6 with blunted responses, and also in 7 age-weight-matched nondiabetic subjects. Rates of plasma glucose decrease and postnadir increase, as well as plasma concentrations of free insulin and of counterregulatory hormones, were measured when insulin was infused alone, and when insulin was infused along with propranolol (a beta1- and beta2-adrenergic receptor antagonist) or metoprolol (a selective beta1-antagonist). Postnadir plasma glucose recovery was decreased in IDDM with blunted plasma glucagon responses (21 ± 0.8 μmol · L-1, P <0.001), but was normal in patients with normal plasma glucagon responses (30 ± 0.4 versus 33 ± 0.5 μmol · L-1 · min-1 in nondiabetic subjects, P = NS). Postnadir plasma glucose recovery was not affected by either propranolol or metoprolol in normal subjects and in IDDM with normal glucagon responses. However, in IDDM with blunted plasma glucagon responses, postnadir plasma glucose recovery was further decreased by propranolol (14 ± 0.6 μmol · L-1 · min-1, P <0.01), but was unaffected by metoprolol (22 ± 0.9 μmol · L-1 · min-1, P= NS). These results demonstrate that, as in normal man, adrenergic mechanisms are not essential for normal plasma glucose recovery from hypoglycemia in IDDM with normal plasma glucagon responses. However, in IDDM with blunted plasma glucagon responses, adrenergic mechanisms become important for glucose counterregulation although they do not fully compensate for the blunted plasma glucagon responses. Since propranolol delayed plasma glucose recovery from hypoglycemia in IDDM with blunted glucagon responses but metoprolol had no effect, the adrenergic contribution to glucose counterregulation appears to be mediated through beta2-adrenergic receptors.

UR - http://www.scopus.com/inward/record.url?scp=0020599851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020599851&partnerID=8YFLogxK

M3 - Article

C2 - 6311652

AN - SCOPUS:0020599851

VL - 32

SP - 887

EP - 893

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 10

ER -